Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Cash from Financing Activities (2019 - 2025)

Keros Therapeutics' Cash from Financing Activities history spans 7 years, with the latest figure at -$378.6 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 601.21% year-over-year to -$378.6 million; the TTM value through Dec 2025 reached -$378.5 million, down 196.59%, while the annual FY2025 figure was -$378.5 million, 196.59% down from the prior year.
  • Cash from Financing Activities reached -$378.6 million in Q4 2025 per KROS's latest filing, down from $140000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $156.8 million in Q1 2024 to a low of -$378.6 million in Q4 2025.
  • Average Cash from Financing Activities over 5 years is $17.1 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 138708.57% in 2022, then crashed 601.21% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $28.4 million in 2021, then surged by 116.13% to $61.4 million in 2022, then rose by 12.76% to $69.3 million in 2023, then rose by 9.08% to $75.5 million in 2024, then plummeted by 601.21% to -$378.6 million in 2025.
  • Per Business Quant, the three most recent readings for KROS's Cash from Financing Activities are -$378.6 million (Q4 2025), $140000.0 (Q3 2025), and $17000.0 (Q2 2025).